INmune Bio Inc expected to post a loss of 15 cents a share - Earnings Preview

What happened

INmune Bio Inc is expected to report results on October 28 for the quarter ending September 30, 2026. Analysts expect a loss of 15 cents per share and no change in quarterly revenue.

Confirmed

Global impact / market context

A loss of 15 cents a share means costs are expected to exceed revenue, so investors will watch whether spending is controlled. The average analyst rating is buy, with a median 12-month price target of $8.00, far above the last close of $1.46.

Analyst inference

The company beat earnings estimates in most recent quarters, which may shape expectations for this report. Analysts left the mean estimate unchanged over three months, suggesting stable views. The high price target versus the low share price signals optimism but also risk.

Analyst inference

What to watch

1. Watch whether reported revenue matches the expectation of no change from a year earlier, since flat revenue would mean growth has stalled while costs continue. Confirmed
2. Watch whether the actual loss per share beats or misses the 15 cent estimate, because past results swung widely between beats and misses. Analyst inference
3. Watch for any company comment on spending plans and cash needs, since continued losses could require raising money or cutting costs. Proposed

Evidence

• Original source link unavailable